Company Overview and News
Cynata Therapeutics Ltd (ASX:CYP) has been granted a patent for its proprietary Cymerus™ mesenchymal stem cell technology in the U.S.
Cynata Therapeutics Ltd (ASX:CYP) has crossed a major milestone by successfully completed the pre-IND (investigational new drug) meeting with the U.S. FDA (Food and Drug Administration).
Glioblastoma Multiforme Pipeline Therapeutics Development 2017 report provides Companies Involved in Therapeutics Development like AbbVie, Novartis AG, Novogen, Merck KGaA and others. Report encapsulates all the dormant and discontinued Glioblastoma Multiforme pipeline projects.
Cynata Therapeutics (ASX:CYP) has received the Notice of Allowance from the U.S. patent office for a patent application tied to its proprietary Cymerus™ stem cell technology.
Global Regenerative Medicine Market Analysis & Forecast to 2021 report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials.
Cynata Therapeutics (ASX:CYP) has some very interesting news on the horizon, with the company entering an ASX trading halt pending an update on its Phase 1 clinical trial. The halt will remain in place until the opening of trade on Wednesday 17th May 2017, or earlier if an announcement will be made to the market.
Research and Markets has announced the addition of the "Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report to their offering.
Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.
Cobalt Blue Holdings (ASX:COB) was only recently minted on the ASX, yet the company has already outlined a rapid growth story.
White Cliff Minerals (ASX:WCN) has near-term gold production potential, and is currently working towards a new JORC Resource for the high-grade Aucu gold project located in the Kyrgyz Republic of central Asia.
Bluechiip (ASX:BCT) has developed an IT based temperature and identification tracking solution for biosamples in the health and life sciences industry.
These events are tailor-made for private and professional investors who have exposure to equities, particularly growth stocks - or indeed anyone who is considering putting their money to work in dynamic sectors such as mining, oil and gas, technology and drug discovery.
Cynata Therapeutics (ASX:CYP) is a stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™.
Legend Mining (ASX:LEG) is exploring on one of Australia's host post codes, the Fraser Range of Western Australia, with partner Creasy Group.
Furthermore, Cynata expects to receive $4 million towards the end of this month via the issue of shares to FUJIFILM, as part of a strategic partnership.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton